Cyclosporin H boosts a new lentivirus-delivered gene therapy with enhanced anti-sickling properties in blood stem cells from ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector ...

Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with Novartis to discover and develop in ...

OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical ...